Objectives. To evaluate damage and variables associated with damage in GCA.
Introduction
GCA is a chronic, granulomatous, large-vessel vasculitis [1] . Damage in GCA may occur secondary to the underlying vasculitis and/or treatment for the disease. Visual impairment and permanent vision loss are particularly dreaded complications of GCA [2, 3] . Additionally, vascular inflammation may lead to large-vessel complications such as arterial stenosis, occlusion, aneurysm or dissection [2, 49] . Glucocorticoids remain the mainstay of treatment for patients with GCA but glucocorticoid-associated adverse effects and morbidity are common [10, 11] .
Given the morbidity from vasculitis and treatment, damage assessment is an important component in the evaluation of patients with GCA. The Vasculitis Damage Index (VDI) is a validated tool to evaluate damage in systemic vasculitis [12] . It contains 64 items grouped into 11 organ-based systems. Only items that have been present for at least 3 months are scored. The VDI has also been shown to have prognostic value, with increased mortality in patients with granulomatosis with polyangiitis (Wegener's) with high VDI or damage in multiple organ systems [13] . However, validation studies of the VDI included only a small number of patients with largevessel vasculitis (six with Takayasu's arteritis and one with GCA) [12] . The Large-Vessel Vasculitis Index of Damage (LVVID) (supplementary Fig. S1 , available at Rheumatology Online) was developed to specifically catalogue damage in GCA and Takayasu's arteritis. Compared with the VDI, the LVVID contains additional items in the ocular, cardiac and peripheral arterial categories that are germane to patients with large-vessel vasculitis and are missing on the VDI, which was designed to address all forms of vasculitis.
The aim of this study was to assess damage and predictors of damage in a longitudinal cohort of patients with GCA using the VDI and LVVID and to inform future efforts to develop and validate standardized measures of damage for use in clinical trials in GCA [14] .
Methods
All data for this study were collected from patients enrolled between 2006 and 2014 in the Vasculitis Clinical Research Consortium Longitudinal Study of Giant Cell Arteritis, a multicentre, prospective, observational cohort from nine academic centres in North America. The study was approved by institutional review boards at each participating site. All participants provided informed consent.
All patients in this cohort meet the 1990 ACR classification criteria for GCA [15] , modified to include patients with giant cell arteritis diagnosed by large-vessel angiography or biopsy. Inclusion criteria were age >50 years with the presence of two or more of the following features: new localized headache, temporal artery abnormality on examination, ESR >40 mm/h by the Westergren method, abnormal temporal artery biopsy and large vessel vasculitis by angiography or biopsy. All subjects were followed prospectively with standardized clinical assessments, including symptoms attributable to active vasculitis, laboratory findings and use of glucocorticoids and/or other immunosuppressive medications. Data from measures of damage (VDI and LVVID) were collected on all patients at study entry and every 6 months. Only items present for at least 3 months were captured in the damage assessment. Damage items were carried forward and were cumulative. Relapse was defined as any new disease activity since the last visit that was attributed to vasculitis by the treating physician after a period of remission (absence of any disease symptoms or findings attributable to vasculitis by the treating physician). The presence of any relapse and the number of relapses were recorded.
Descriptive statistics were used. Chi-square and Fischer's exact tests were used for comparison of categorical variables. Logistic regression analyses were performed to evaluate the association of clinical variables (age, sex, disease duration from diagnosis, presence of relapse as defined above and number of relapses) with the outcome of damage. Since this is not an inception cohort, risk factors for the presence of new damage during followup were also assessed in the subset of patients with newly diagnosed GCA (defined as enrolled into the cohort 490 days from diagnosis).
Results
The Vasculitis Clinical Research Consortium GCA cohort
The study included 204 patients with GCA: 156 (76%) female, 197 (96%) Caucasian. The mean age at diagnosis of GCA was 71.3 years (S.D. 8.3). The median duration from diagnosis to entry into the cohort was 3.7 months (25th75th quartile 1.016.5). A total of 117 subjects (57%) enrolled in the cohort within 6 months of diagnosis. The mean duration of follow-up for the cohort was 3.5 years (S.D. 1.9). Temporal artery biopsy was performed in 136 subjects (67%) and was positive in 116 (85%).
Damage at study entry
The median number of damage items at entry into the cohort was 1 (range 07) on the VDI and 1 (range 012) on the LVVID. At enrolment into the cohort, at least one damage item was present in 110 patients (54%) on the VDI and 123 (60%) on the LVVID. In the subset with one or more damage item on a given instrument, the median number of damage items was 2 (range 19) on the VDI and 3 (range 116) on the LVVID.
The most frequently observed items of damage at entry into the cohort are shown in Table 1 .
At least one damage item was recorded in 46/114 (40%) patients diagnosed 4180 days prior to study entry on the VDI compared with 64/87 (74%) with a disease duration >180 days (P < 0.0001). Similarly, 55/116 (47%) patients diagnosed 4180 days prior to study entry had one or more item by the LVVID compared with 68/87 (78%) with a disease duration >180 days (P < 0.0001). The median damage in patients diagnosed 4180 days was 0 (range 05) on the VDI compared with 2 (range 07) in subjects with >180 days disease duration. The median damage in patients diagnosed 4180 days was 0 (range 07) on the LVVID compared with 2 (range 012) in subjects diagnosed >180 days.
Damage accrual during follow-up
After a mean follow-up of 3.5 years, 161 (80%) patients had one or more item of damage [median 2 (range 09)] on the VDI while 166 (82%) patients had one or more damage item [median score 3 (range 016)] on the LVVID. At least one new item of damage was recorded in 112 (55%) patients on the VDI [median number of new items 1 (range 08)] and in 117 (60%) patients on the LVVID [median number 1 (range 08)]. The number of patients with three or more damage items on the VDI was 39%, with 13% of patients having five or more damage items [16] . A comparison of the frequency of damage items at enrolment and the last follow-up is shown in Table 2 ). The most frequently observed new items of damage are shown in Fig. 1 .
Predictors of damage in patients with GCA
Predictors for the presence of any damage at the last follow-up for the whole cohort were evaluated using univariate analyses. Disease duration was the only predictor of the presence of any damage at the last follow-up; the risk of damage increased 22% for every additional year of disease duration [OR 1.22 (95% CI 1.04, 1.45)] (Table 3 ).
Predictors of damage in patients diagnosed with GCA 490 days Risk factors for the presence of new damage during follow-up was assessed in the subset of 93 patients with newly diagnosed GCA (defined as enrolled into the cohort 490 days from diagnosis). In this subset, the risk of new damage at the last follow-up decreased 30% for each additional relapse [OR 0.70 (95% CI 0.51, 0.97)] ( Table 3) .
The distribution of relapses among the 93 newly diagnosed patients was as follows: zero relapses in 32 patients (34%), one relapse in 32 (34%), two relapses in 8 (9%) and three or more relapses in 21 (23%). Clinical variables were compared between 93 patients with newly diagnosed GCA (diagnosed 490 days) (i) with and without new items of damage and (ii) with and without relapses (Table 4) .
Medication use also did not differ in 93 patients with newly diagnosed GCA with or without new damage. Among patients diagnosed 490 days, use of glucocorticoid at the time that new damage was observed was noted in 55 of 60 (92%) patients with new damage compared with 17 of 17 (100%) patients without new damage. Additional immunosuppressive therapies during followup were used in 12 of 60 (20%) patients with new damage compared with 4 of 17 (24%) patients without new damage.
Performance of the outcome measures
There were multiple items in the different categories on both the VDI and LVVID that never applied to any patient with GCA in this cohort ( Table 5 ). The LVVID provided more granularity on the different components of damage that are frequently observed in patients with GCA, especially the ocular and peripheral arterial categories (Table 1) . Specifically, for the ocular manifestations, ischaemic optic neuropathy, a dreaded complication of GCA, was captured on the LVVID but not on the VDI. While the VDI captures data on limb claudication, the peripheral vascular damage items on the LVVID separated them into upper and lower extremity claudication. Other large-vessel damage items, including arterial occlusions/ thrombosis and aneurysms, were also captured on the LVVID. Additionally, weight gain (>10 lb) was systematically queried on the LVVID, which led to more complete capture of this frequently observed adverse effect of glucocorticoid therapy in patients with GCA.
Discussion
This is the largest longitudinal study to assess damage in patients with GCA. After a median observation of 3.5 years, the majority of patients with GCA had at least one item of damage. New items of damage were observed in more than half of the patients in this cohort, with the majority of new damage items being related to treatment. Damage is the irreversible consequence of the condition and may represent the cumulative burden of the disease experienced by the patient [17, 18] . Patients with GCA may experience irreversible consequences of the disease, including permanent vision loss, chronic ischaemic symptoms and infarction or large-artery complications. Furthermore, in prospective observational studies, relapses were frequently observed in patients with GCA [1922] and often necessitate an increase in glucocorticoid treatment. This is the first study to systematically assess damage in patients with GCA using the VDI, a validated tool, and the LVVID, an instrument that was specifically developed for use in large-vessel vasculitis.
More than 80% of patients in the cohort had one or more damage item at the last follow-up, which is similar to what has been reported in studies evaluating damage in Baseline, n (%) Follow-up, n (%) P-value Baseline, n (%) Follow-up, n (%) P-value other systemic vasculitides [17, 2325] . However, the median VDI and LVVID scores in patients with GCA were lower than those reported in other forms of systemic vasculitis [13, 17, 2325] . The majority of the damage items in patients with GCA were captured in four main categories: ocular, cardiac, peripheral vascular and musculoskeletal. Additionally, on the LVVID, many patients also had findings in the 'other' category due to the item of weight gain, which was included in this index. The burden of disease-associated manifestations at study entry was high, with limb claudication in 19%, ischaemic optic neuropathy in 12% (captured only on the LVVID) and permanent vision loss in 9%. Aneurysms were present in 3% patients (captured only on the LVVID), although this manifestation of disease may be underrecognized if imaging of the aorta is not performed routinely.
Similar to what has been reported for other forms of vasculitis, new damage items that may be related to disease or its treatment, particularly glucocorticoids, were observed in patients with GCA [17, 2426] . Prior studies have also found a higher risk of treatment-related damage in older subjects [13, 16, 25] . Most of the new damage items in patients with GCA in the current study were associated with treatment. The disease-associated items of damage were predominantly large-vessel arterial events, including absent pulses, limb claudication, arterial occlusions and arterial damage requiring intervention, suggesting a higher burden of disease in patients with extracranial manifestations of GCA.
When evaluating the entire cohort, disease duration was associated with the presence of damage at the last followup. Given that most new damage items are glucocorticoid related, this likely reflects prolonged glucocorticoid exposure in these patients. In ANCA-associated vasculitis (AAV), disease relapses have been associated with increased damage [16, 24, 27, 28] . However, when evaluating the subset of 93 patients with newly diagnosed GCA (490 days from entry into the cohort), a higher number of relapses was associated with a lower likelihood of new damage during follow-up. This finding was not well explained, especially since the majority of the new damage over time in this cohort was related to the toxicity of treatment with glucocorticoids. Symptoms at disease presentation or the frequency of a temporal artery biopsy positive for GCA was not different in subjects with or without relapses or new damage. Furthermore, the use of immunosuppressive medications other than glucocorticoids was not different in newly diagnosed patients with new damage items compared with newly diagnosed patients without new items of damage. While cumulative glucocorticoid doses were not available, glucocorticoid use at the time of new damage was no different between patients with or without new damage items when restricted to patients with newly diagnosed disease. In the future, tools such as the glucocorticoid toxicity index may be helpful in better quantifying glucocorticoid-associated damage but warrant further investigation [29] . Many items that are queried on the VDI and LVVID did not apply to any patient with GCA. The LVVID systematically captured important damage items including ischaemic optic neuropathy, arterial occlusions, aneurysms and damage requiring surgery that were not present on the VDI. The LVVID did not include absent pulses, which was queried on the VDI; however, this finding is a proxy for arterial stenoses, which is captured on the LVVID.
The strengths of this study include the prospective design with standardized serial assessments. This cohort included subjects with the full range of manifestations of GCA, including a substantial number with largeartery disease, a now commonly recognized subgroup [5, 3032] . The conduct of the study at multiple centres in North America adds to the generalizability of the results.
Potential limitations of the study include that the cohort includes patients evaluated at tertiary care referral centres and may include a higher proportion of patients with relapsing or severe disease compared with community practices; however, the multicentred nature of the cohort and the inclusion of so many patients at each site helps increase the range of disease and generalizability of the study. Additionally, data on the cumulative doses of glucocorticoids were not available and would have been of interest relative to several items of damage.
Patients with GCA should be monitored for cumulative disease and treatment-associated damage. This study provides information for data-driven development of damage-related outcomes for future use in clinical trials and clinical practice. These data also provide support to simplify the VDI/LVVID approach to damage assessment through removal of items not applicable to the vast majority of patients with GCA. Better therapeutics for GCA that target disease activity and reduce the cumulative burden of disease-and treatment-associated damage are needed. The present study highlights the importance of including damage assessment in future clinical trials of GCA.
